2016 BBA Winner Profile: Company of the Year - GlaxoSmithKline K.K.

Dec. 1, 2016


The ninth British Business Awards were held on November 11 2016 at the Hilton Hotel Tokyo | GlaxoSmithKline K.K. named Company of the Year.

In 2016, British Business Awards (BBA) Company of the Year nominees were required to show excellence and outstanding achievement in all aspects of their organisation in Japan, focusing on the past 12 months. The British Chamber of Commerce in Japan (BCCJ) is delighted to announce the winner as GlaxoSmithKline K.K. (GSK).

GSK was recognised for helping people to do more, feel better, and live longer; for widening access to GSK products, no matter where a person lives or what they can afford to pay; and for raising awareness of this commitment as a visible contributor to Japanese society.

Accepting the award on behalf of his team, Philippe Fauchet OBE, President of GlaxoSmithKline K.K said:

"We are very honored to be awarded 'Company of the Year' at the 2016 British Business Awards and we thank the judges for having recognized us among many other good candidates with a very valuable dossier.

"We have strived to make industry leading changes to modernise our business and ensure our long-term sustainability in alignment with our four values, and with specific attention to 'patient focus'.

"This recognition of British business excellence reflects the dedication and commitment of GSK Japan employees to improve the way we do business, contributing to medical science and information in Japan as well as to our community and people in need through our CSR activities under our 'Orange banner'.

"We will continue to 'do more' to serve the people living in Japan so that they feel better and live longer.”

GSK has made industry-leading changes to modernise and reshape their business model to ensure that patients are always given top priority. Individual sales targets for sales representatives have been eliminated and instead, sales staff are evaluated on other quality KPI indicators. The practice of payments to doctors for speaking on behalf of GSK has also been abolished. This unique business model has been praised for its transparency and has been covered by several media outlets in Japan.

The company was instrumental in advocating the G7 leaders at the May 2016 Ise-Shima summit in Japan to guarantee concrete measures to improve global health security. As a science-led healthcare company, GSK is also committed to the agenda and works actively on many of the issues feeding into it, including combatting emerging infectious diseases such as Ebola and Zika, anti-microbrial resistance and pandemics.

The company has 40 new assets in the world most extensive portfolios of R&D, 80% of which have the potential to be first-in-class. In Japan, 2015 marked a successful year for R&D with regulatory approvals for nine new products ensuring the business maintains its status as the market leader in filing for approvals.

GSK is the recognised leader, by market share, in the respiratory, anti-histamine, benign prostatichyperplasia, spasticity and anti-HIV in Japan. It occupies second place in the markets for nasalcorticosteroid, epilepsy, anti-Parkinson's, pulmonary hypertension and hepatitis B medicines.

The company strongly believes in contributing to the development of medical and life sciences. The GSK Independent Medical Education was established this year; the first programme of grants aimed at helping enhance the quality of medical care and education in Japan.

GSK has led the way in the field in developing innovative child-resistant, senior-friendly packaging, winning the 2015 Japan Packaging Contest last year.

Highly committed to Diversity & Inclusion, by the middle of 2016, 50% of GSK board members and 46% of new hires were female. 47 employees are differently-abled, including three who have competed in the Deaflympics or Paralympic Games. Fifteen male staff took childcare leave last year and the company advocates work-life balance and a performance-driven rewards system.

GSK Japan employees contributed 32 million yen to Save the Children from January 2015 to June 2016 through its global partnership program, Orange United, which aims to save the lives of 1 million children worldwide. Some of this funding was used to support children in Tohoku and Kumamoto who were affected by the earthquakes.

The company also established its Orange Scholarship in 2011, funded through energy-saving in GSK offices. The scholarships have supported the education of 30 pharmacy students from parts of northeast Japan affected by the tsunami.

All photos by Anthony Tran at Life14

__________________________________________________________________

Related media

2016 BBA nominee photo gallery HERE

2016 BBA photos HERE

2016 BBA Nominee list in full HERE

2016 BBA Judging begins HERE

2016 What do BBA judges look for? HERE